Active Ingredient History
Temsirolimus is an intravenous drug for the treatment of renal cell carcinoma (RCC), developed by Wyeth Pharmaceuticals and approved by the FDA in late May 2007, and was also approved by the European Medicines Agency (EMEA) on November 2007. It is a derivative of sirolimus and is sold as Torisel. Temsirolimus is an inhibitor of mTOR (mammalian target of rapamycin). Temsirolimus binds to an intracellular protein (FKBP-12), and the protein-drug complex inhibits the activity of mTOR that controls cell division. Inhibition of mTOR activity resulted in a G1 growth arrest in treated tumor cells. When mTOR was inhibited, its ability to phosphorylate p70S6k and S6 ribosomal protein, which are downstream of mTOR in the PI3 kinase/AKT pathway was blocked. In in vitro studies using renal cell carcinoma cell lines, temsirolimus inhibited the activity of mTOR and resulted in reduced levels of the hypoxia-inducible factors HIF-1 and HIF-2 alpha, and the vascular endothelial growth factor. NCATS
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Adenocarcinoma (Phase 1/Phase 2)
Anemia, Refractory (Phase 2)
Arthritis, Rheumatoid (Phase 2)
Astrocytoma (Phase 2)
Brain Neoplasms (Phase 2)
Brain Stem Neoplasms (Phase 1)
Breast Neoplasms (Phase 3)
Breast Neoplasms, Male (Phase 1/Phase 2)
Burkitt Lymphoma (Phase 2)
Carcinoma (Phase 1)
Carcinoma, Endometrioid (Phase 2)
Carcinoma, Hepatocellular (Phase 2)
Carcinoma, Islet Cell (Phase 2)
Carcinoma, Mucoepidermoid (Phase 1)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Carcinoma, Squamous Cell (Phase 2)
Carcinoma, Transitional Cell (Phase 1)
Carcinoma, Verrucous (Phase 2)
Castleman Disease (Phase 1)
Central Nervous System (Phase 1)
Chronic Limb-Threatening Ischemia (Phase 3)
Colonic Neoplasms (Phase 1)
Colorectal Neoplasms (Phase 2)
Desmoplastic Small Round Cell Tumor (Phase 2)
Diffuse Intrinsic Pontine Glioma (Phase 1)
Digestive System Neoplasms (Phase 1)
Endometrial Neoplasms (Phase 2)
Erdheim-Chester Disease (Phase 1)
Fallopian Tube Neoplasms (Phase 2)
Fibrosarcoma (Phase 2)
Ganglioneuroblastoma (Phase 2)
Gastrointestinal Stromal Tumors (Phase 2)
Genital Diseases, Female (Phase 2)
Genital Neoplasms, Female (Phase 1)
Glioblastoma (Phase 2)
Glioma (Phase 2)
Gliosarcoma (Phase 2)
Hamartoma (Phase 2)
Head and Neck Neoplasms (Phase 1/Phase 2)
Healthy Volunteers (Phase 1)
Hepatoblastoma (Phase 3)
Hodgkin Disease (Phase 2)
Intestinal Neoplasms (Phase 2)
Kidney Neoplasms (Phase 3)
Leiomyosarcoma (Phase 2)
Leukemia (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia-Lymphoma, Adult T-Cell (Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Leukemia, Myeloid, Chronic-Phase (Phase 2)
Leukemia, Myelomonocytic, Chronic (Phase 2)
Liposarcoma (Phase 2)
Liver Diseases (Phase 1)
Liver Neoplasms (Phase 2)
Lung Diseases (Phase 1)
Lung Neoplasms (Phase 2)
Lymphangioleiomyomatosis (Phase 1)
Lymphoma (Phase 3)
Lymphoma, B-Cell (Phase 1)
Lymphoma, B-Cell, Marginal Zone (Phase 2)
Lymphoma, Follicular (Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 2)
Lymphoma, Large-Cell, Immunoblastic (Phase 2)
Lymphoma, Mantle-Cell (Phase 3)
Lymphoma, Non-Hodgkin (Phase 4)
Lymphoma, Primary Cutaneous Anaplastic Large Cell (Phase 1/Phase 2)
Lymphoma, T-Cell, Peripheral (Phase 1)
Melanoma (Phase 2)
Multiple Myeloma (Phase 2)
Multiple Sclerosis, Relapsing-Remitting (Phase 2)
Myelodysplastic Syndromes (Phase 2)
Nasopharyngeal Carcinoma (Phase 2)
Neoplasm Metastasis (Phase 3)
Neoplasms ()
Neoplasms, Mesothelial (Phase 1)
Neoplasms, Squamous Cell (Phase 1/Phase 2)
Nerve Sheath Neoplasms (Phase 2)
Neuroblastoma (Phase 2)
Neuroendocrine Tumors (Phase 2)
Neurofibromatosis 2 (Phase 1)
Oligodendroglioma (Phase 2)
Osteosarcoma (Phase 2)
Ovarian Diseases (Phase 2)
Ovarian Neoplasms (Phase 2)
Pancreatic Neoplasms (Phase 2)
Peripheral Arterial Disease (Phase 3)
Pheochromocytoma (Phase 1)
Pinealoma (Phase 1)
Prostatic Neoplasms (Phase 2)
Prostatic Neoplasms, Castration-Resistant (Phase 1/Phase 2)
Rhabdomyosarcoma (Phase 3)
Rhabdomyosarcoma, Alveolar (Phase 3)
Rhabdomyosarcoma, Embryonal (Phase 3)
Salivary Gland Neoplasms (Phase 2)
Sarcoma (Phase 2)
Sarcoma, Ewing (Phase 2)
Sarcoma, Synovial (Phase 2)
Small Cell Lung Carcinoma (Phase 2)
Soft Tissue Neoplasms (Phase 1)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Thyroid Neoplasms (Phase 2)
Tongue Neoplasms (Phase 2)
TOR Serine-Threonine Kinases (Phase 2)
Triple Negative Breast Neoplasms (Phase 1)
Urethral Neoplasms (Phase 1/Phase 2)
Urinary Bladder Neoplasms (Phase 2)
Uterine Cervical Neoplasms (Phase 2)
Uterine Diseases (Phase 1/Phase 2)
Uterine Neoplasms (Phase 2)
Waldenstrom Macroglobulinemia (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
